Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endothelin and L-Arginine in Racial Differences in Vasoconstriction
NCT03679780Phase 1Completed
- Sponsor
- The University of Texas at Arlington
- Start
- Oct 2018
- Primary completion
- Jul 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of BQ-123, BQ-788 and arginine in cardiovascular disease (CVD) (4 arms), sponsored by The University of Texas at Arlington. Primary endpoint: Vasodilatory Response to Endothelin Receptor-A/B Blockers and L-Arginine following local heating. Started Oct 2018; status: completed.
02
Drugs
BQ-123BQ-788arginine
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03679780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679780.